KRRO · NASDAQ · Biotechnology

Korro Bio (KRRO)

Develops RNA-editing therapeutics around OPERA and GalNAc-delivered liver programs.

$12.21
Pre-market+0.28 (+2.35%)
At close$11.93(−2.53%)

Something off on this page? Send us feedback.

Next report
Nov 11, 2026
estimated · in 69 days
EPS estimate
−$1.25
Revenue estimate
$187.5K
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$2.26−$2.49−$2.74−$1.92−$5.32−$1.69−$1.07Pending
Estimate−$2.33−$2.60−$2.54−$2.61−$1.93−$1.60−$1.34−$1.25
Surprise+3.0%+4.2%−7.9%+26.4%−175.6%−5.6%+20.1%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$2.3M$2.6M$1.5M$1.1M$1.3M$1.5MPending
Estimate$426.9K$320.8K$425.0K$700.0K$761.2K$214.3K$187.5K
Surprise+497.3%+355.1%+156.5%+85.7%+600.0%

History

DateEstimateReportedSurprise
Nov 2026−$1.25
Aug 2026−$1.34−$1.07+20.1%
May 2026−$1.60−$1.69−5.6%
Mar 2026−$1.93−$5.32−175.6%
Nov 2025−$2.61−$1.92+26.4%

The latest year is open to everyone — the 24 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Dec 2022
Sep 2022
Jun 2022
Mar 2022
Dec 2021
Sep 2021
Jun 2021
Mar 2021
Dec 2020
Sep 2020
Jun 2020
Mar 2020
Dec 2019
Sep 2019
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 11, 2026−$1.25$187.5K
Aug 6, 2026−$1.34−$1.07+20.1%$214.3K$1.5M+600.0%+5.4%
May 7, 2026−$1.60−$1.69−5.6%$761.2K−6.5%
Mar 12, 2026−$1.93−$5.32−175.6%$700.0K$1.3M+85.7%+11.3%
Nov 12, 2025−$2.61−$1.92+26.4%$425.0K$1.1M+156.5%−79.3%

The latest year is open to everyone — the 24 quarters behind it read with an account.

Sign in
Aug 12, 2025
May 7, 2025
Mar 18, 2025
Nov 12, 2024
Aug 13, 2024
May 14, 2024
Mar 29, 2024
Nov 2, 2023
Aug 10, 2023
May 12, 2023
Dec 30, 2022
Sep 29, 2022
Jun 30, 2022
Mar 31, 2022
Dec 30, 2021
Sep 29, 2021
Jun 29, 2021
Mar 31, 2021
Dec 31, 2020
Sep 30, 2020
Jun 30, 2020
Mar 31, 2020
Dec 31, 2019
Sep 30, 2019